Kiniksa Pharmaceuticals International, plc (KNSA): Cost of Revenue
$77.67M
Year ended 2025-12-31
$80.60M
Trailing 12 months to 2026-03-31
+50.3%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $77.67M | +27.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $60.91M | +82.3% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $33.41M | +45.9% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $22.89M | +151.6% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $9.10M | n/a | 2022-02-24, From 2021-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $77.67M | +27.5% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $326.20M | -52.1% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $100.71M | +161.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $400.94M | -18.9% |
| Insmed Inc (INSM) | 2025-12-31 | $122.94M | +43.4% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
Compare KNSA, SUPN, AMPH, PCRX side by side · Screen every company in Pharmaceutical Preparations ↗